FDA’s Social Media Consumer Outreach Up
The pilot involved several CDER employees working together with OEA employees to respond to drug related inquiries posted on FDA’s Facebook page.
In 2014, The FDA’s Office of External Affairs (OEA) and Center for Drug Evaluation and Research (CDER) began a 90-day pilot program to improve consumer engagement by enhancing its social media responses, specifically to drug related inquiries more quickly and proactively. The pilot involved several CDER employees working together with OEA employees to respond to drug related inquiries posted on FDA’s Facebook page. The pilot was successful and as a result has become a permanent program.
Other highlights from the social media update are the dashboards offered-OEA Dashboard within the OC Administrative Offices Dashboard. Also noted in the dashboards is the delay of an implementation for an FDA-wide social media policy, targeted now for end of May 2016.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
